Healthcare - Biotechnology - NASDAQ - US
$ 2.53
-6.3 %
$ 179 M
Market Cap
-1.38
P/E
CASH FLOW STATEMENT
-86.2 M
OPERATING CASH FLOW
79 M
INVESTING CASH FLOW
691 K
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Nkarta, Inc.
| Net Income | -118 M |
| Depreciation & Amortization | 5.87 M |
| Capital Expenditures | -28.1 M |
| Stock-Based Compensation | 17.2 M |
| Change in Working Capital | 10.9 M |
| Others | 4.05 M |
| Free Cash Flow | -114 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (117.5) | (113.8) | (86.1) | (91.4) | (21.1) | (0.3) |
| Depreciation & Amortization | 5.9 | 2.6 | 1.8 | 0.8 | 0.4 | 0.2 |
| Deferred Income Tax | 0 | 0 | 3.2 | 0.7 | (0.1) | 0 |
| Stock Based Compensation | 17.2 | 16.9 | 14.5 | 6.7 | 0.9 | 0.2 |
| Other Operating Activities | (2.7) | 3.6 | 0.3 | 40.4 | (0.7) | 0.5 |
| Change in Working Capital | 10.9 | 33.7 | (1.6) | (0.8) | 2.2 | (5.3) |
| Cash From Operations | (86.2) | (57.0) | (67.9) | (43.5) | (18.4) | (5.2) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (28.1) | (47.1) | (5.0) | (7.5) | (1.9) | (0.8) |
| Other Items | 107.2 | (137.6) | 37.6 | (202.6) | (16.4) | 0 |
| Cash From Investing Activities | 79.0 | (184.7) | 32.5 | (210.1) | (18.3) | (0.8) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 64.3 | 6.0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.7 | 1.8 | 1.2 | 0.4 | 87.1 | 87.5 K |
| Cash From Financing Activities | 0.7 | 219.0 | 1.2 | 329.8 | 49.6 | 87.5 K |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (6.5) | (22.7) | (34.2) | 76.2 | 12.9 | (5.9) |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (114.3) | (104.1) | (73.0) | (51.0) | (20.3) | (5.9) |